Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behcet's disease-like mouse model

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 415-425

  Shim, J ^a,b   Byun, H O ^a   Lee, Y D ^a   Lee, E S ^a   Sohn, S ^a,b  

^a Ajou University   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 6; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHCET DISEASE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; EAR LOBE; HERPES SIMPLEX VIRUS; IN VIVO STUDY; INFLAMMATION; INOCULATION; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; BEHCET SYNDROME; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE THERAPY; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; MALE; MICE; MICE, INBRED ICR; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

HUMAN HERPESVIRUS 1; MUS; SIMPLEXVIRUS;

EID: 62549106162     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.180     Document Type: Article

References (62)

1. Akdeniz N, Esrefoglu M, Kele MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore 2004; 33: 596-599.
2. Kallen KJ. The role of trans signalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002; 1592: 323-343.
3. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem 1990; 265: 621-636.
4. Hirano T. Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992; 62: 60-65.
5. Yamakawa Y, Sugita Y, Nagatani T, Takahashi S, Yamakawa T, Tanaka S et al. Interleukin-6 in patients with Behcet's disease. J Dermatol Sci 1996; 11: 189-195.
6. LinksWang CR, Chuang CY, Chen CY. Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behçet's syndrome. Clin Exp Rheumatol 1992; 10: 599-602.
7. Bardak Y, Aridoan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm 2004; 12: 53-58.
8. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S et al. Adamantiades-Behçet's disease: Interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000; 292: 279-284.
9. Choi B, Hwang Y, Kwon HJ, Lee ES, Park KS, Bang D et al. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008; in press.
10. Seçkin D, Akpolat T, Oltulu Y, Erkan D, Cantürk T, Adam B et al Serum lipoprotein (a) levels in Behçet's disease. Br J Dermatol 1995; 133: 342.
11. Müftüolu AU, Yazici H, Yurdakul S, Tüzün Y, Pazarli H, Güngen G et al. Relation of serum Creactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235-239.
12. al-Dalaan A, al-Sedairy S, al-Balaa S, al-Janadi M, Elramahi K, Bahabri S. Enhanced interleukin 8 secretion in circulation in patients with Behçet's disease. J Rheumatol 1995; 22: 904-907.
13. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades- Behçet's disease: Serum IL-8 is more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201: 37-39.
14. Sayinalp N, Ozcebe OI, Ozdemir O, Haznedarolu IC, Dündar S, Kirazli S. Cytokines in Behçet's disease. J Rheumatol 1996; 23: 321-322.
15. Sohn S, Lee ES, Bang D, Lee S. Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998; 8 21-23.
16. Adam B, Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol 2004; 18: 318-320.
17. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002; 11: 87-93.
18. Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A et al Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin Immunol Immunopathol 1997; 82: 12-17.
19. Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007; 104: 12099-12104.
20. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and downregulation of Smad7. J Immunol 2004; 172: 5149-5153.
21. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
22. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8: 1390-1397.
23. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
24. Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: Master regulators of innate and adaptive immunity. Immunol Rev 2004; 202: 96-105.
25. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.
26. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-160.
27. Mudter J, Neurath MF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007; 13: 1016-1023.
28. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM et al. Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus. J Clin Immunol 2007; 27: 461-466.
29. Paludan SR. Requirements for the induction of interleukin-6 by herpes simplex virus-infected leukocytes. J Virol 2001; 75: 8008-8015.
30. Kanangat S, Babu JS, Knipe DM, Rouse BT. HSV-1-mediated modulation of cytokine gene expression in a permissive cell line: Selective upregulation of IL-6 gene expression. Virology 1996; 219: 295-300.
31. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368: 339-342.
32. LeBlanc RA, Pesnicak L, Cabral ES, Godleski M, Straus SE. Lack of interleukin-6 (IL-6) enhances susceptibility to infection but does not alter latency or reactivation of herpes simplex virus type 1 in IL-6 knockout mice. J Virol 1999; 73: 8145-8151.
33. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126: 1121-1133.
34. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M et al. Foxp3 Inhibits ROR{gamma}t-mediated IL-17A mRNA Transcription through Direct Interaction with ROR{gamma}t. J Biol Chem 2008; 283: 17003-17008.
35. Henness S, Johnson CK, Ge Q, Armour CL, Hughes JM, Ammit AJ. IL-17A augments TNF-alpha-induced IL-6 expression in airway smooth muscle by enhancing mRNA stability. J Allergy Clin Immunol 2004; 114: 958-964.
36. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 2007; 178: 271-279.
37. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M et al Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: Induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10: 1969-1980.
38. McKee AS, Pearce EJ. CD25+CD4+ cells contribute to Th2 polarization during helminth infection by suppressing Th1 response development. J Immunol 2004; 173: 1224-1231.
39. van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW et al. TNFR-shedding by CD4+CD25+ regulatory T cells inhibits the induction of inflammatory mediators. J Immunol 2008; 180 2747-2751.
40. Noguchi D, Wakita D, Tajima M, Ashino S, Iwakura Y, Zhang Y et al. Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol 2007; 19: 1431-1440.
41. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: Contribution of CD4+CD25+ regulatory cells within the central nervous system. J Immunol 2005; 175 3025-3032.
42. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med 2004; 200: 273-276.
43. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-979.
44. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109: 131-140.
45. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 531-562.
46. Veldhoen M, Hocking RJ, Atkins CL, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24 179-189.
47. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemiconset juvenile idiopathic arthritis. Arthritis Rheum 2005; 52: 818-825.
48. Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421: 744-748.
49. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
50. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316.
51. Lew W, Chang JY, Jung JY, Bang D. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease. Br J Dermatol 2008; 158: 505-511.
52. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathological significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman's disease. Blood 2008; 112: 3959-3964.
53. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A et al. IL-6 Receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: Results from a 24-week multicentre Randomised Placebo Controlled Trial. Ann Rheum Dis 2008; 67: 1516-1523.
54. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 1998; 159: 181-185.
55. Hattori Y, Maitani Y. DNA/Lipid complex incorporated with fibronectin to cell adhesion enhances transfection efficiency in prostate cancer cells and xenografts. Biol Pharm Bul 2007; 30: 603-607.
56. Pawar RM, Dhinakar Raj G, Senthil Kumar TMA, Raja A, Balachandran C. Effect of siRNA mediated suppression of signaling lymphocyte activation molecule on replication of peste des petits ruminants virus in vitro. Virus Res 2008; 136: 118-123.
57. Hsu HC, Yang PA, Wang J, Wu Q, Myers R, Chen J et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9: 124-126.
58. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K et al IL-17B and IL-17C Are Associated with TNF-alpha Production and Contribute to the Exacerbation of Inflammatory Arthritis. J Immunol 2007; 179: 7128-7136.
59. Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun 2007; 29: 187-194.
60. Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T et al Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab 2007; 25: 277-285.
61. Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007; 19: 695-702.
62. Sonobe Y, Liang J, Jin S, Zhang G, Takeuchi H, Mizuno T, Suzumura A. Microglia express a functional receptor for interleukin-23. Biochem Biophys Res Commun 2008; 370: 129-133.